Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

(2012) L. Burt Nabors et al.   CANCER

The Role of Integrins in Glioma Biology and Anti-Glioma Therapies

(2011) Ghazaleh Tabatabai et al.   CURRENT PHARMACEUTICAL DESIGN

Advances in malignant glioma drug discovery

(2011) David A Reardon et al.   Expert Opinion on Drug Discovery

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

(2011) Mark R. Gilbert et al.   JOURNAL OF NEURO-ONCOLOGY

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Treatment of high-grade glioma in children and adolescents

(2011) T. J. MacDonald et al.   NEURO-ONCOLOGY

Cilengitide induces autophagy-mediated cell death in glioma cells

(2011) S. L. Lomonaco et al.   NEURO-ONCOLOGY

Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group

(2011) K. J. Cohen et al.   NEURO-ONCOLOGY

Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches

(2011) Kathryn Beal et al.   Radiation Oncology

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting integrins in malignant glioma

(2010) Ghazaleh Tabatabai et al.   Targeted Oncology

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro

(2009) Gabriele D. Maurer et al.   NEURO-ONCOLOGY

The Integrin Antagonist Cilengitide Activates αVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells

(2009) Gian Carlo Alghisi et al.   PLoS One

Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiforme

(2008) David A Reardon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency

(2008) Tom Mikkelsen et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012

(2008) Tobey J. MacDonald et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY